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recommended until recently in unconscious successfully resuscitated cardiac
arrest (CA) patients, especially after initial shockable rhythm. A randomized
controlled trial published in 2013 observed similar outcome between a 36 °C-
targeted temperature management (TTM) and a 33 °C-TTM. The main aim of
our study was to assess the impact of this publication on physicians regarding
their TTM practical changes. METHODS: A declarative survey was performed
using the webmail database of the French Intensive Care Society including
3229 physicians (from May 2014 to January 2015). RESULTS: Five hundred
and eighteen respondents from 264 ICUs in 11 countries fulfilled the survey
(16 %). A specific attention was generally paid by 94 % of respondents to TTM
(hyperthermia avoidance, normothermia, or TH implementation) in CA patients,
whereas 6 % did not. TH between 32 and 34 °C was declared as generally
maintained during 12-24 h by...
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Changes in cardiac arrest patients’ 
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Corinne Audoin11, Xavier Monnet12, Pierre‑François Laterre13 and For the SRLF Trial Group
Abstract 
Background: Therapeutic hypothermia (TH between 32 and 34 °C) was recommended until recently in unconscious 
successfully resuscitated cardiac arrest (CA) patients, especially after initial shockable rhythm. A randomized controlled 
trial published in 2013 observed similar outcome between a 36 °C‑targeted temperature management (TTM) and a 
33 °C‑TTM. The main aim of our study was to assess the impact of this publication on physicians regarding their TTM 
practical changes.
Methods: A declarative survey was performed using the webmail database of the French Intensive Care Society 
including 3229 physicians (from May 2014 to January 2015).
Results: Five hundred and eighteen respondents from 264 ICUs in 11 countries fulfilled the survey (16 %). A specific 
attention was generally paid by 94 % of respondents to TTM (hyperthermia avoidance, normothermia, or TH imple‑
mentation) in CA patients, whereas 6 % did not. TH between 32 and 34 °C was declared as generally maintained 
during 12–24 h by 78 % of respondents or during 24–48 h by 19 %. Since the TTM trial publication, 56 % of respond‑
ents declared no modification of their TTM practice, whereas 37 % declared a practical target temperature change. 
The new temperature targets were 35–36 °C for 23 % of respondents, and 36 °C for 14 %. The duration of overall TTM 
(including TH and/or normothermia) was declared as applied between 12 and 24 h in 40 %, and between 24 and 48 h 
in 36 %. In univariate analysis, the physicians’ TTM modification seemed related to hospital category (university versus 
non‑university hospitals, P = 0.045), to TTM‑specific attention paid in CA patients (P = 0.008), to TH durations (<12 
versus 24–48 h, P = 0.01), and to new targets temperature (32–34 versus 35–36 °C, P < 0.0001).
Conclusions: The TTM trial publication has induced a modification of current practices in one‑third of respondents, 
whereas the 32–34 °C target temperature remained unchanged for 56 %. Educational actions are needed to promote 
knowledge translations of trial results into clinical practice. New international guidelines may contribute to this effort.
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Background
Targeted temperature management (TTM) has been 
shown to improve outcome in adult patients successfully 
resuscitated from cardiac arrest (CA) [1–4]. However, 
several issues such  as the optimal level of TTM or the 
optimal method of cooling still remained unsolved [4, 
5]. The recent publication of the large TTM trial by 
Nielsen and co-workers seemed to answer, at least par-
tially, those questions [6]. No main outcome differ-
ences were observed between the two evaluated levels 
of TTM: 33 °C (corresponding previously to therapeutic 
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hypothermia: TH) versus 36 °C both applied during 28 h. 
However, this trial mostly included out-of-hospital CA 
patients with relatively short no-flow durations occur-
ring from both initial non-shockable and shockable 
rhythms. Conversely, the European trial had previously 
compared a 33  °C-TTM group versus a control group 
without a specific temperature management protocol 
in patients after CA from shockable rhythm only and 
more prolonged no-flow durations [7]. Finally, the three 
main randomized trials evaluating TTM after CA seem 
to highlight that all TTM procedures (e.g., 36  °C-TTM 
and 33 °C-TTM) are similarly beneficial when compared 
with non-TTM regimen [1, 2, 6–8]. This issue, also rein-
forced by a recent meta-analysis, has been recalled by 
the International Liaison Committee On Resuscitation 
(ILCOR) experts, possibly to avoid any definitive aban-
don of TTM implementation after CA [9, 10]. Indeed 
these experts assume that the published studies do not 
support a treatment strategy where TTM is abandoned 
but support a strategy where either 33 or 36  °C-TTM 
remains an important component of post-CA treatment 
[9]. However, to the best of our knowledge, no study has 
to date evaluated the potential impact of these different 
TTM trials on the post-CA management.
Following the main studies on TH published in 2002 [1, 2], 
the initial surveys showed relatively low rates of TH imple-
mentation overall ranging from 13 to 28 % with variations 
according to countries [11–15]. After the first TH guidelines 
published in 2003 [16], widespread TH implementation 
seemed to occur progressively. Indeed, two consecutive sur-
veys performed in Poland found that the number of inten-
sive care units (ICUs) using TH increased threefold in the 
5-year period of 2005–2010 [17, 18]. Similarly, two consec-
utive surveys found a major increase in TH use from 28.4 
to 85.6 % between 2006 and 2010 in the United Kingdom 
[15, 19]. Finally, a declarative survey performed in France 
reported up to 98 % adherence to recommendations regard-
ing TH [20]. As the pendulum may swing back to an adap-
tive “lighter” TTM or a non-TTM approach in resuscitated 
CA patients, we decided to conduct a survey to assess the 
potential impact of the recent studies published on the prac-
tical management of such patients.
Methods
A declarative survey was performed among 3 229 phy-
sician members of the French Intensive Care Society 
(FICS/SRLF), including numerous French-speaking 
countries. The first email was sent on May 23, 2014, fol-
lowed by eight new mailings sent monthly until Janu-
ary 8,  2015 (several answers per ICU were allowed). 
Respondents received no compensation for their partici-
pation in the survey.
A questionnaire written in French was developed by 
a senior intensivist experienced in CA and TTM, and 
implemented using SurveyMonkey®. The study group 
tested the questionnaire and worked on rephrasing and 
improvement. The survey was made of 74 questions, of 
which 19 needed mandatory answers and included those 
focusing on TTM practice in CA patients (see Additional 
file  1). Briefly, the questionnaire was divided into four 
parts: (1) Characteristics of the ICU and the respond-
ent; (2) General and cardiovascular management of CA; 
(3) TTM in CA patients (indication for TH use, changes 
induced by the Nielsen trial [6], cooling methods); and 
(4) Prognostication in CA patients. Except for quanti-
tative questions, responses were obtained either using 
a bimodal answer (“yes/no”) or a 4-point Likert scale 
(structured as “always/frequently/sometimes/never”).
Statistics
Quantitative variables were expressed as mean (stand-
ard deviation) when following a Gaussian distribution 
or median (interquartile range 25–75 %) otherwise, and 
were compared using the Student t or Mann–Whitney 
test, respectively. Qualitative variables were expressed 
as frequencies (95  % confidence interval) calculated by 
angular transformation, and were compared using the 
Chi Square or Fisher exact probability test for categorical 
variables. Data were tested for normality using the Shap-
iro Normality Test. Multivariate analyses were performed 
using logistic regression. All tests were two-sided with 
5 % significance, and performed using the R software (R 
package version 2.14.1.6, Vienna, Austria).
Results
Five hundred and eighteen respondents fulfilled the sur-
vey (16 %), representing an absolute number of 264 ICUs 
(France: 219; Belgium: 18; Africa: 16; others from Europe: 
9; Canada: 2). General characteristics of respondents and 
their ICUs are described in Table  1.  The distribution of 
responses over time is depicted in Additional file 2: Fig-
ure S1.
Targeted temperature management (TTM)
Specific attention is generally paid to temperature man-
agement (normothermia, avoiding hyperthermia, or 
TTM implementation) in successfully resuscitated and 
unconscious CA patients as declared by 94 % of respond-
ents, mainly using TH in 89  %. The reasons why TH is 
not applied are depicted in Additional file  2: Figure S2. 
Indications of TH implementation in successfully resus-
citated and unconscious CA patients are described in 
Table  2. Temperature monitoring after CA is mainly 
performed using a bladder probe as reported by 42  % 
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of respondents, and/or an esophageal probe by 41  % of 
respondents (Additional file 2: Figure S3).
TH was declared as never induced using intravenous 
cold fluids by 38  % of respondents (Table  3). TH was 
reported to be always induced and/or maintained using 
basic external methods (fan and ice packs) by 34  %, 
whereas other methods of cooling were more rarely 
used. TH between 32 and 34 °C was declared as generally 
maintained during 12–24  h by 78  % of respondents, or 
during 24–48 h by 19 %. Passive rewarming was predom-
inantly used by 66 % of respondents. The usual reported 
rate for active rewarming was 0.5  °C/h in 53  % and 
0.3 °C/h in 25 % of the cases.
Since the TTM trial publication [6], 56 % of respond-
ents declared no modification of their TTM practice, 
whereas 37  % declared a practical target temperature’s 
change (Additional file  2: Figure S4). This modification 
is applied in all CA patients in 52  % or in specific CA 
patients in 34 %, mainly in CA from cardiac origin (see 
details in Additional file 2: Figure S5). The new tempera-
ture targets presently preferred by respondents after the 
Nielsen’s trial are depicted in Fig. 1 [6]. The overall dura-
tion of the TTM after CA (i.e., including hypothermia 
whatever its level and/or normothermia) is now mainly 
applied between 12 and 24 h by 40 % of respondents, and 
between 24 and 48 h by 36 % (Fig. 2). Univariate analysis 
describing factors associated with modifications of the 
Table 1 Characteristics of  respondents (number of 
respondents: N) and their intensive care unit
Results are expressed as n (%) unless specified otherwise
Type of hospital (N = 509)
 Public university hospital 249 (49)
 Public non‑university hospital 228 (45)
 Private hospital 27 (5)
 Other 5 (1)
Country (N = 515)
 France 448 (87)
 Other in Europe 38 (7)
 Africa 25 (5)
 Canada 4 (1)
ICU staff (N = 500)
 Attending full‑time physicians, mean ± SD 7.2 ± 3.8
 Resident and fellow, mean ± SD 4.8 ± 4.2
ICU beds, mean ± SD (N = 448) 15 ± 7
ICU activity during the last full year (2013) prior to the present study
 Overall admissions (N = 500)
  <300 22 (4)
  300–500 125 (25)
  500–800 145 (29)
  >800 208 (42)
 Admissions for CA (N = 518)
  <10 70 (14)
  10–20 154 (30)
  20–30 76 (15)
  30–40 60 (12)
  40–50 45 (9)
  >50 113 (22)
 TH implementation (N = 384)
  <10 74 (19)
  10–20 120 (31)
  20–30 54 (14)
  30–40 45 (12)
  40–50 34 (9)
  >50 57 (15)
Use of a written CA procedure (N = 509) 221 (43)
No available CA procedure in the ICU 259 (52)
In‑hospital cath lab performing coronary  
angiography (N = 518)
363 (70)
With a 24 h/24 h availability 353 (97)
Table 2 Indications for  therapeutic hypothermia imple-
mentation after successfully resuscitated and unconscious 
cardiac arrest patient (N respondents)
Results are expressed as n (%)
CA cardiac arrest
a Ventricular fibrillation/pulseless ventricular tachycardia
b Asystole/pulseless electrical activity
Out‑of‑hospital CA from initial shockable rhythma (N = 403)
 Always 258 (64)
 Frequently 75 (19)
 Sometimes 24 (6)
 Never 29 (7)
 Do not know 17 (4)
Out‑of‑hospital CA from initial non‑shockable rhythmb (N = 403)
 Always 134 (33)
 Frequently 129 (32)
 Sometimes 73 (18)
 Never 51 (13)
 Do not know 16 (4)
In‑hospital CA from initial shockable rhythma (N = 399)
 Always 229 (57)
 Frequently 85 (21)
 Sometimes 38 (10)
 Never 32 (8)
 Do not know 15 (4)
In‑hospital CA from initial non‑shockable rhythmb (N = 398)
 Always 117 (29)
 Frequently 122 (31)
 Sometimes 86 (22)
 Never 60 (15)
 Do not know 13 (3)
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temperature level occurring after the TTM trial publica-
tion is described in Table 4.  
General treatments along TTM
During the TTM period, patients were reported to always 
receive sedatives by 85  % of respondents (midazolam 
83 % and/or propofol 40 %), analgesics by 78 % (sufenta-
nil 64 % and fentanyl 23 %), and neuromuscular blockers 
by 47  % (cisatracurium 67  % and atracurium 29  %). A 
specific protocolized insulin treatment for glycemic con-
trol after CA was always used by 59 %. Fifty-six percent 
of respondents reported to never use a specific protocol 
regarding the PaO2 control, and 43 % to never use a spe-
cific protocol regarding the PaCO2 control. Additional 
results regarding the use of coronary angiography after 
the return of spontaneous circulation (ROSC), regarding 
the targeted arterial blood pressure after ROSC, regard-
ing the initial cardiopulmonary resuscitation, regarding 
the use of brain computerized-tomography scanner, use 
of ventricular assist devices in refractory CA and in case 
of severe post-CA shock, and regarding prognostication 
after CA are described in the online supplementary files 
(Additional file  2: Figures S6, S7, S8, and S9; Tables S1, 
S2).
Discussion
In this declarative survey, specific attention was gener-
ally paid by 94 % of respondents to TTM in unconscious 
and successfully resuscitated CA patients. The optimal 
target temperature to reach after CA remains unchanged 
for 56 % of respondents, whereas 37 % declare to target 
a new temperature following the TTM trial publication 
[6]. The current targets temperature are 32–34  °C (or 
33  °C) in 60  %, 35–36  °C in 23  %, 36  °C in 14  %. TTM 
modifications were more frequently declared by physi-
cians working in university hospitals. At present, TH is 
never induced using intravenous cold fluids by 38  % of 
respondents.
TTM modifications
International guidelines recommended until recently the 
use of 32–34 °C-targeted TH in successfully resuscitated 
unconscious out-of-hospital adult CA patients, mainly 
for initial shockable rhythm [3]. However, the optimal 
level of the target temperature remains unknown. In 
the publication by Nielsen and co-workers, no main dif-
ferences were observed between the two levels of target 
temperature: 33 °C (corresponding previously to TH) and 
36 °C [6]. Considering debates after this large trial [7, 8, 
21], ILCOR experts published a new recommendation 
regarding the TTM use after CA [9]. Indeed, since the 
results of the TTM publication, a significant proportion 
of physicians may shift back in their practice and aban-
don all sort of TTM after CA, and resume practice as 
mainly reported before the 2002 pivotal trials. Our survey 
confirms that roughly one-third of physicians decided to 
modify their current practice, mainly by using a smooth 
depth of TTM. However, most physicians seemed not to 
abandon the use of temperature management after CA, 
applying predominantly the previous recommended 
33  °C target or a new 36  °C-TTM. Only a minority of 
Table 3 Methods of  cooling used for  therapeutic hypo-
thermia implementation after  cardiac arrest (N respond-
ents)
Results are expressed as n (%)
TH therapeutic hypothermia
Cold intravenous fluid infusion to induce TH (N = 396)
 Always 48 (12.1)
 Frequently 95 (24.0)
 Sometimes 100 (25.2)
 Never 152 (38.4)
 Do not know 1 (0.3)
Basic surface cooling (fans, ice packs) to induce and/or maintain TH 
(N = 395)
 Always 136 (34.4)
 Frequently 91 (23.0)
 Sometimes 93 (23.6)
 Never 74 (18.7)
 Do not know 1 (0.3)
External water blanket cooling to induce and/or maintain TH (N = 394)
 Always 57 (14.5)
 Frequently 34 (8.6)
 Sometimes 26 (6.6)
 Never 274 (69.5)
 Do not know 3 (0.8)
External air blanket cooling to induce and/or maintain TH (N = 396)
 Always 28 (7.1)
 Frequently 38 (9.6)
 Sometimes 59 (14.9)
 Never 269 (67.9)
 Do not know 2 (0.5)
External advanced surface cooling gel pads to induce and/or maintain 
TH (N = 399)
 Always 10 (2.5)
 Frequently 30 (7.5)
 Sometimes 25 (6.3)
 Never 328 (82.2)
 Do not know 6 (1.5)
Intravascular device to induce and/or maintain TH (N = 395)
 Always 28 (7.0)
 Frequently 37 (9.2)
 Sometimes 37 (9.2)
 Never 298 (74.3)
 Do not know 1 (0.3)
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physicians (6  %) herein declared to be unaware of any 
TTM after CA. This is concordant with a previous survey 
performed in France, observing a global 98 % adherence 
to recommendations regarding TTM [20]. Two-third of 
respondents declared in our survey not to have changed 
the target temperature, despite the TTM trial [6]. Among 
respondents who changed their target temperature, the 
majority decided to choose a TTM set around 36  °C, 
whereas some respondents decided to target the pre-
vious 32–34  °C range. One may hypothesize that the 
majority of respondents were not yet deeply convinced 
by the TTM trial or remained unaware of its publication, 
whereas some physicians possibly did not have previous 
protocol in their unit regarding the target temperature, 
or used a protocol targeting a temperature different from 
the recommended 32–34  °C range. Finally, our results 
seem in accordance with other studies describing that 
new scientific evidences resulting from recent rand-
omized clinical trials are sometimes poorly implemented 
in clinical practice, as it has been shown for instance in 
the tight glycemic control area [22].
Interestingly, most of the respondents who changed 
their target temperature finally decided to choose pref-
erentially an intermediate range between 35 and 36  °C, 
instead of the 36 °C precisely reported in the TTM trial. 
However, the 2015 ILCOR guidelines, recently published 
[23], recommend at present “TTM for adults with out-
of-hospital CA with an initial shockable rhythm at a con-
stant temperature between 32 and 36 °C for at least 24 h. 
Similar suggestions are made for out-of-hospital cardiac 
0
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Fig. 1 Distribution of the new targets temperature expressed as absolute number (percentage) after the Nielsen’s publication [6] (n = 423 respond‑
ents, expressed as percentage). Other targets (n = 9, 2.1 %) were documented as follows: 37 °C (n = 4, 0.9 %), 34 °C (n = 3, 0.7 %), and 35 °C (n = 2, 
0.5 %)
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Fig. 2 Distribution of the durations of the overall targeted temperature management period (n = 413 respondents, expressed as percentage). 
Other durations of the overall targeted temperature management phase were documented as follows: =72 h (2), >72 h (4) miscellaneous (4)
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arrest with a non-shockable rhythm and in-hospital car-
diac arrest.” In our survey, physicians changing their tar-
get temperature mostly applied these modifications for 
all CA patients, despite that the TTM trial was focused 
on out-of-hospital CA from cardiac origin. This sug-
gests that physicians could use an adaptive TTM, since 
Table 4 Comparison of respondents declaring a target temperature’s changes versus those without target temperature’s 
changes after the TTM study publication (univariate analysis)
Results are expressed as n (%) unless expressed otherwise
TTM targeted temperature management, TT targeted temperature, CA cardiac arrest, ECLS extracorporeal life support, ABP arterial blood pressure, TH therapeutic 
hypothermia
a This item corresponds to the following question “In practice, do you generally pay a specific attention to temperature management in successfully resuscitated and 
unconscious CA patients”
b This item corresponds to the following question “In practice, do you generally use TH in successfully resuscitated and unconscious CA patients”
Respondents who  
changed their TT
Respondents who did not  
changed their TT
P value
University hospital 90/171 (52.6) 97/224 (43.3) 0.045
Public non‑university hospital 65/171 (38.0) 115/224 (51.4)
Private hospital 15/171 (8.8) 9/224 (4.0)
Others 1/171 (0.6) 3/224 (1.3)
Number of ICU beds 15.9 ± 7.9 15.1 ± 6.6 0.32
Number of residents and fellows 5.4 ± 5.9 4.5 ± 2.8 0.099
Number of full‑time physicians 7.6 ± 4.7 6.9 ± 2.9 0.12
Use of a written CA protocol 77/170 (45.3) 102/224 (45.5) 0.87
Number of admissions <500/year 45/168 (26.8) 65/223 (29.1) 0.21
Number of admissions >500/year 123/168 (73.2) 158/223 (70.9)
Number of CA admissions <30/year 98/172 (57.0) 126/227 (55.5) 0.87
Number of CA admissions >30/year 74/172 (43.0) 101/227 (44.5)
Number of TH <30/year 108/154 (70.1) 129/212 (60.8) 0.22
Number of TH >30/year 46/154 (29.9) 83/212 (39.2)
In‑hospital cath‑lab 124/172 (72.1) 161/227 (70.9) 0.87
ECLS use for refractory CA 92/172 (53.5) 101/227 (44.5) 0.07
Optimal ABP targeted 156/171 (91.2) 190/219 (86.8) 0.19
Specific TTM after CAa 166/171 (97.1) 213/227 (93.8) 0.008
No specific TTM after CAa 5/171 (2.9) 14/227 (6.1)
TH after CAb 143/172 (83.1) 212/227 (93.4) 0.003
No TH after CAb 27/172 (15.7) 15/227 (6.6)
TH duration
 <12 h 8/159 (5.0) 2/212 (0.9) 0.01
 ≥12 h/≤24 h 124/159 (80.0) 166/212 (78.3)
 >24 h/≤48 h 24/159 (15.1) 44/212 (20.8)
 >48 h 3/159 (1.9) 0/212 (0.0)
Active rewarming 57/156 (36.5) 98/213 (46.0) 0.087
New TT
 32–34 °C 45/171 (26.3) 194/225 (86.2) <0.0001
 35–36 °C 78/171 (45.6) 15/225 (6.7)
 36 °C 44/171 (25.7) 11/225 (4.9)
 Other 4/171 (2.4) 5/225 (2.2)
Overall TTM duration
 <12 h 7/169 (4.1) 3/220 (1.4) 0.074
 ≥12 h/≤24 h 75/169 (44.4) 81/220 (36.8)
 >24 h/≤48 h 61/169 (36.1) 83/220 (37.7)
 >48 h/≤72 h 24/169 (14.2) 42/220 (19.1)
 Other 2/169 (1.2) 11/220 (6.0)
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the TTM trial publication [6], mainly regarding the target 
temperature and the selection of patients that will receive 
TTM. However, these choices remain in accordance with 
these new ILCOR guidelines [23].
As expected in our study, the target temperature’s 
change was related to the TH/TTM characteristics per-
formed by physicians (choice by physicians to perform 
TH/TTM in unconscious CA patients), and to the new 
target temperature. However, practical target tempera-
ture’s change seemed also related to the hospital category 
(i.e., university hospital or not). Interestingly, the TH/
TTM durations seemed also associated to this tempera-
ture change: longer TTM durations seemed more often 
declared by physicians that did not change their practice. 
This could be paradoxical with the fact that the TTM 
trial preferentially used a prolonged duration of TTM as 
compared with the 2002 pivotal trials [1, 2, 6]. It can be 
argued that the respondents who changed their practice 
decided that TH should be no longer useful and conse-
quently shortened the TH/TTM durations. However, 
prospective studies are warranted to confirm this issue.
Modifications of the cooling methods
The majority of respondents herein declared to use basic 
external methods to implement TH. Close to our results, 
external methods were used in 54 % of cases in a previ-
ous survey conducted in France [20]. Similarly, other sur-
veys observed that surface cooling and/or ice packs were 
mostly used in ICUs, usually reaching about 50–60  % 
[18, 19, 24, 25]. Our survey confirms that simple and 
less expensive methods, such as basic and external cool-
ing, may represent the first choice for most physicians, 
despite that new arguments could modify this issue [26, 
27].
Most of respondents declared in our survey that they 
never induce TH using intravenous cold fluids. In some 
countries where TH seemed underused (reaching 21.7, 
43, and 55.1  % of cases), cold fluids as an induction 
method of cooling are also infrequently used (8.5, 7.4, 
and 22 % of respondents, respectively) [18, 25, 28]. Con-
versely, in United Kingdom with an 86 % use of TH, 71 % 
of respondents stated that TH was usually induced by the 
rapid infusion of cold fluids [19]. In Germany, cold packs 
and cold infusions were both equally used in about 60 %, 
mainly because of their lower cost [29]. In the study by 
Merchant and co-workers, non-United States respond-
ents seemed more likely to cool with cold fluids as com-
pared with United States respondents (36 versus 28  %, 
respectively), while ice packs were used in 40 and 60 %, 
respectively [30]. While 41 % of French ICUs previously 
declared to use cold fluid for TH induction [31], our sur-
vey observed that such cooling was presently not used in 
38  % of cases. Indeed, two large randomized controlled 
studies using cold intravenous fluids to induce TH in the 
prehospital setting did not find improvement in outcome 
as compared with a standard TTM management, lead-
ing to important doubts regarding this specific cooling 
method for TH induction [32, 33]. This is also concord-
ant with the new ILCOR guidelines that recently “recom-
mends against prehospital cooling with rapid infusion of 
large volumes of cold intravenous fluid” [23]. However, 
whether “prehospital cooling using a rapid infusion of 
large volumes of cold intravenous fluid immediately after 
ROSC is not recommended, it may still be reasonable 
to infuse cold intravenous fluid where patients are well 
monitored and a lower target temperature (e.g., 33 °C) is 
the goal” [34].
Other evaluated parameters along TTM
The previous published survey performed in France 
observed similar or close results to ours regarding asso-
ciated treatments used during TTM [20]. However, we 
observed a slightly higher use of propofol (40  % pres-
ently versus 10 % in the previous study) [20]. This could 
be related to some recent publications showing a possi-
ble superiority regarding neurological prognostication by 
using short half-life sedatives [35]. Additionally, we found 
a possible lower percentage of use of neuromuscular 
blocking agents during TTM (47 % presently versus 97 % 
previously) [20]. To the best of our knowledge, our study 
is the first to evaluate the extremely low use of a specific 
protocol regarding PaO2 and PaCO2, despite the probable 
impact of such interventions [8, 36, 37]. This contrasts 
with glycemic control protocols that were here reported 
to be frequently used, suggesting that this parameter 
seems important for respondents as previously suggested 
in CA [38]. To the best of our knowledge, our survey is 
also the first to describe other TTM’s associated treat-
ments of the post-CA period, such uses of coronary 
angiography and ventricular assist devices, and the arte-
rial pressure target after CA along TTM (see the online 
supplement).
Limitations
While offering new insights mainly regarding TTM 
implementation, our study has several limitations. 
First, the percentage of respondents is only 16  %, limit-
ing results generalization. However, despite a median 
reported response rate reaching 63.3  % [39], lower 
response rates have also been described in other declara-
tive surveys, between 2.9 and 18.1  % [40–42]. The usual 
response rates in the field of TH range from 13 to 98 %, 
with the lower limit roughly observed in our study [12, 
15, 20, 24, 43, 44]. Second, as our survey is purely declara-
tive, discrepancies may exist between our results and the 
real-life practice. We conducted this survey using the 
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FICS website database including only physicians but not 
nurses. However, it is unlikely that other trained staff or 
nurses could apply different TTM prescriptions as com-
pared with those declared in the present survey. Third, it 
could be argued that our survey only concerns intensiv-
ists working in France. However, the FICS includes several 
responders from numerous French-speaking countries, 
herein reaching 13  % of respondents of this survey. 
Because only French-speaking physicians were here able 
to respond, our results can mainly be applied for French-
speaking countries. Considering the high rate (98  %) of 
TH implementation in France as previously published 
[20], our result regarding the percentage of TH changes 
induced by the TTM publication seems likely. Finally, our 
survey collected answers from some responders work-
ing in the same ICU that could lead to bias. However, 264 
ICUs from 11 countries were involved in the present sur-
vey, showing a large representative response to correctly 
evaluate the TTM and cooling changes.
Conclusion
The TTM trial publication showing no main difference 
between 36 and 33 °C after CA has induced a modifica-
tion of current practices in one-third of respondents. 
However, the 32–34  °C target temperature remained 
unchanged for 56 % of respondents. Prospective epidemi-
ologic studies may evaluate the impact on patients’ out-
come of those practices. Educational actions are needed 
to promote better knowledge translations of trial results 
and guidelines into clinical practice.
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